Recent Updates on CDK4/6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.

EP. 1: Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer

June 15th 2022

Massimo Cristofanilli, MD, FACS, provides a historical overview of the HR+/HER2- metastatic breast cancer (mBC) treatment landscape.

EP. 2: HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium

June 15th 2022

Expert Harold Burstein, MD, PhD, breaks down the treatment armamentarium for patients with HR+/HER2- metastatic breast cancer.

EP. 3: Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer

June 22nd 2022

Shared insight on how best to select frontline therapy, alone or in combination, for patients with HR+/HER2- mBC.

EP. 4: PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy

June 22nd 2022

Time-to-chemotherapy results of the PALOMA-2 and -3 trials in HR+/HER2- metastatic breast cancer, which combined frontline palbociclib and endocrine therapy.

EP. 5: MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy

June 29th 2022

Highlights from the MONALEESA-2 and -3 trials combining frontline ribociclib with endocrine therapy in patients with HR+/HER2- metastatic breast cancer.

EP. 6: MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant

June 29th 2022

Expert perspectives on the pooled analysis from MONARCH 2 and MONARCH 3, combining frontline abemaciclib with fulvestrant.

EP. 7: HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors

July 6th 2022

Richard Finn, MD, considers data behind all three approved CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer and how they compare.

EP. 8: Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer

July 6th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

EP. 9: HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors

July 13th 2022

A brief review of molecular testing’s role in HR+/HER2- metastatic breast cancer and how certain driver mutations can impact care.

EP. 10: Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC

July 13th 2022

Key opinion leaders share insight on various mechanisms of resistance to frontline therapy in patients with HR+/HER2- metastatic breast cancer.